Medtronic Expands Ortho Biologics Presence With Osteotech Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Medtronic is shoring up its orthopedic biologics business through the acquisition of demineralized bone matrix marketer Osteotech for $123 million, announced Aug. 17
You may also be interested in...
Medtronic’s Hawkins To Retire; Company Sets External Search For New CEO
Medtronic Chairman and CEO William Hawkins is retiring after just three years in the firm’s top spot, a move that may reflect the company’s desire to accelerate change and diversification in the face of sluggish growth in signature businesses.
Medtronic’s Hawkins To Retire; Company Sets External Search For New CEO
Medtronic Chairman and CEO William Hawkins is retiring after just three years in the firm’s top spot, a move that may reflect the company’s desire to accelerate change and diversification in the face of sluggish growth in signature businesses.
Medtronic Q1 Revenues Fall 4% On Decreased Hospital Utilization
Medtronic is blaming a 4% decline in corporate first quarter sales on worsening hospital utilization rates in the U.S. The businesses most affected were Cardiac Rhythm Disease Management and Spine, CEO Bill Hawkins reported during an Aug. 24 earnings call